Cirrhosis
Conditions
Keywords
Vaccinal coverage, vaccination, cirrhosis, cirrhotic, COVID, hepatitis B, hepatitis A, influenzae virus, pneumococcus, tetanus, poliomyelitis
Brief summary
the purpose of this study is to estimate vacinal coverage against hepatitis A and B viruses, pneumococcus, diphtheria/tetanos and poliomyelitis, influenza virus and covid in cirrhotic patients followed in general hospitals of France and to show the
Detailed description
Cirrhosis is a serious liver disease very common in France, affecting nearly 200,000 people. These patients have an impaired immune response. They are, therefore, more frequently prone to bacterial, viral and fungal infections and these are more severe with high mortality. 30-50% of cirrhotics admitted to a hospital ward have sepsis, with pneumococcal bacterial infections being particularly severe. The risk of developing seasonal influenza is 5.7 times higher in cirrhotics with a risk of mortality multiplied by 169. COVID19 infection is responsible for a very high mortality (34%) in case of severe resuscitation form. Acute infections with hepatitis A (HAV) and B (HBV) viruses frequently lead to worsening liver failure decompensating to cirrhosis, and sometimes life-threatening fulminant hepatitis. Finally, chronic infection with the hepatitis B virus combined with another etiology of cirrhosis accelerates the course of liver disease and promotes the occurrence of hepatocellular carcinoma. Limiting the incidence of viral and bacterial infections in these patients is crucial. The High Authority of Health (HAS) published recommendations in 2007 advising patients with cirrhosis vaccinations against hepatitis A and B viruses, influenza and against bacterial pneumococcal infections, confirmed by the High Council of Public Health. There are few data on vaccination coverage among cirrhotic patients. An unpublished French study from 2000 revealed low vaccination rates: 34% for pneumococcus, 55% for influenza, 32 to 42% for the hepatitis B virus and 20 to 38% for the hepatitis A virus. No recent studies have assessed the impact of the HAS recommendations. The purpose of this study is to estimate vacinal coverage against hepatitis A and B viruses, pneumococcus, diphtheria/tetanos and poliomyelitis, influenza virus and covid in cirrhotic patients followed in general hospitals of France
Interventions
OTHERquestionnaire
patients will complete a vaccination questionnaire
Sponsors
Centre Hospitalier Sud Francilien
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* adult patient * histologically proven or asserted cirrhosis on a combination of clinical, biological, endoscopic and radiological criteria * follow-up of cirrhosis \> 6 months * subject informed of the study and not having objected to it.
Exclusion criteria
* immunosuppression not related to liver disease: HIV, variable common immune deficiency, chemotherapy, anatomical splenectomy, immunosuppressive treatments for non-hepatic disease * vaccine contraindication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage fully immunization coverage | Day 0 | percentage of patients fully vaccinated against polio DT, seasonal influenza, HAV, HBV, pneumococcal and COVID19 in our sample |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| percentage DTpolio immunization coverage | Day 0 | Percentage of vaccination against DTPolio |
| percentage HAV immunization coverage | Day 0 | Percentage of vaccination against HAV |
| percentage HBV immunization coverage | Day 0 | Percentages of vaccination against HBV |
| percentage Pneumococcal immunization coverage | Day 0 | Percentages of vaccination against pneumococcaL |
| percentage Influenza virus immunization coverage | Day 0 | Percentage of vaccination against seasonal influenza |
| percentage COVID immunization coverage | Day 0 | Percentage of vaccination against COVID19 |
Countries
France
Outcome results
None listed